Milrinone is a phosphodiesterase inhibitor, a cardiotonic drug with positive inotropic and vasodilating effects, which can be used to treat acute or chronic refractory congestive heart failure.
Millinone is a cardiotropic drug, belonging to phosphodiesterase inhibitors. By inhibiting phosphodiesterase, the drug can increase the concentration of cyclic adenosine phosphate and calcium in cardiomyocytes, thereby effectively strengthening myocardial contractility and increasing cardiac output, so as to exert positive muscle strength. In addition, Milrinone can also play a vasodilator role by directly acting on the small arteries.
milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival.
Milrinone, is a medication used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, recent studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.
Overall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival.
Avemu parechje fabbriche d'alta qualità cù una cuuperazione prufonda, chì ponu furnisce i prudutti d'alta qualità è i prezzi competitivi. È pudemu ancu dà sconti per l'acquistu grossu. E cooperemu cù parechje cumpagnie prufessiunali di spedizioni di merci, ponu furnisce i prudutti in modu sicuru è lisu à e vostre mani. U tempu di consegna hè di circa 3-20 ghjorni dopu a cunferma di pagamentu.
Analisi
|
Specificazione
|
Risultatu
|
Test method
|
Physical Description
|
|
|
|
Apparizione
|
White Powder
|
White Powder |
Visual
|
Odore
|
Characteristic
|
Characteristic
|
Organoleptic
|
Particle size
|
90% pass 80 mesh
|
90% pass 80 mesh
|
80 Mesh Screen
|
Chemical Tests
|
|
|
|
Assay (Lutein)
|
99%
|
90.15%
|
HPLC
|
Loss on drying
|
5.0% Max
|
1.82%
|
5g/105ºC/2hrs
|
Ash Contents
|
5.0% Max
|
1.12%
|
2g/525ºC/3hrs
|
Residual Solvents
|
50.0 ppm, Only Ethanol
|
<30.0 ppm
|
/
|
Heavy metals
|
5.0 ppm Max
|
<3.0 ppm
|
AAS
|
Lead
|
3.0 ppm Max
|
<1.0 ppm
|
AAS
|
Arsenic
|
3.0 ppm Max
|
<1.0 ppm
|
AAS
|
Microbiology Control
|
|
|
|
Total Bacteria Count
|
1,000cfu/g Max
|
<280cfu/g
|
AOAC
|
Yeast & Mold
|
100cfu/g Max
|
<10cfu/g
|
AOAC
|
Coliform
|
30.0 MPN/g Max
|
<3.0 MPN/g
|
AOAC
|
Cunclusioni
|
Complies with the standards.
|
||
General Status
|
Non-GMO, ISO Certificated.
|
Milrinone is a PDE3 (phosphodiesterase 3) inhibitor that exhibits vasodilator and positive inotropic effects. Milrinone's positive inotropic activity can be inhibited by carbachol (sc-202092). Research indicates that Milrinone can increase platelets and enhance cAMP levels. Milrinone is an inhibitor of PDE3A and PDE3B.
Milrinone, commonly known and marketed as the drug Primacor, is a medication used in patients suffering from heart failure. Milrinone is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility. Milrinone also works to vasodilate vessels which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. Milrinone has been used in those suffering from heart failure for many years.
1. Sò una fabbrica o una sucietà cummerciale ?
Semu una cumpagnia chì integra l'industria è u cummerciu, chì furnisce un serviziu one-stop. OEM puderia esse accettatu.
2. Fornite mostri? Hè gratis o extra?
Campioni gratuiti. A tarifa di trasportu di u campione deve esse pagata da u vostru latu.
3. Avete qualchì certificatu riguardanti u cuntrollu di qualità ?
Certificazione ISO 9001: 2008 per assicurà a qualità.
4. Chì duverebbe furnisce per avè una citazione?
Pls ci informa di u tipu di produttu chì avete bisognu, quantità di ordine, indirizzu è esigenze specifiche. A citazione serà fatta per a vostra riferenza in tempu.
5. Chì tipu di metudu di pagamentu preferite ? Chì tipu di termini sò accettati?
Termini di consegna accettati: FOB, CFR, CIF, EXW;
Valuta di Pagamentu accettata: USD;
Tipu di pagamentu accettatu: T / T, Western Union; Paypal, Assicuranza cummerciale.
Lingua parlata: inglese.
categurie di prudutti